FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3049375212> ?p ?o ?g. }

• W3049375212 endingPage "1039" @default.
• W3049375212 startingPage "1030" @default.
• W3049375212 abstract "Abstract Aim To describe the first Australian cases of severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV2) disease (COVID‐19) pneumonia treated with the interleukin‐6 receptor antagonist tocilizumab. Methods Retrospective, open‐label, real‐world, uncontrolled, single‐arm case series conducted in 2 tertiary hospitals in NSW, Australia and 1 tertiary hospital in Victoria, Australia. Five adult male patients aged between 46 and 74 years with type 1 respiratory failure due to COVID‐19 pneumonia requiring intensive care unit (ICU) admission and biochemical evidence of systemic hyperinflammation (C‐reactive protein greater than 100 mg/L; ferritin greater than 700 μg/L) were administered variable‐dose tocilizumab. Results At between 13 and 26 days follow‐up, all patients are alive and have been discharged from ICU. Two patients have been discharged home. Two patients avoided endotracheal intubation. Oxygen therapy has been ceased in three patients. Four adverse events potentially associated with tocilizumab therapy occurred in three patients: ventilator‐associated pneumonia, bacteremia associated with central venous catheterization, myositis and hepatitis. All patients received broad‐spectrum antibiotics, 4 received corticosteroids and 2 received both lopinavir/ritonavir and hydroxychloroquine. The time from first tocilizumab administration to improvement in ventilation, defined as a 25% reduction in fraction of inspired oxygen required to maintain peripheral oxygen saturation greater than 92%, ranged from 7 hours to 4.6 days. Conclusions Tocilizumab use was associated with favorable clinical outcome in our patients. We recommend tocilizumab be included in randomized controlled trials of treatment for patients with severe COVID‐19 pneumonia, and be considered for compassionate use in such patients pending the results of these trials." @default.
• W3049375212 created "2020-08-21" @default.
• W3049375212 creator A5012416527 @default.
• W3049375212 creator A5012597525 @default.
• W3049375212 creator A5018125923 @default.
• W3049375212 creator A5026850267 @default.
• W3049375212 creator A5028175606 @default.
• W3049375212 creator A5030088258 @default.
• W3049375212 creator A5030697207 @default.
• W3049375212 creator A5036503908 @default.
• W3049375212 creator A5038396319 @default.
• W3049375212 creator A5044390712 @default.
• W3049375212 creator A5045920784 @default.
• W3049375212 creator A5048235044 @default.
• W3049375212 creator A5048487224 @default.
• W3049375212 creator A5049486575 @default.
• W3049375212 creator A5051274602 @default.
• W3049375212 creator A5063550038 @default.
• W3049375212 creator A5065071305 @default.
• W3049375212 creator A5065680312 @default.
• W3049375212 creator A5071551825 @default.
• W3049375212 creator A5072401570 @default.
• W3049375212 creator A5072544168 @default.
• W3049375212 creator A5074377658 @default.
• W3049375212 creator A5079436807 @default.
• W3049375212 creator A5088837358 @default.
• W3049375212 date "2020-08-01" @default.
• W3049375212 modified "2023-10-16" @default.
• W3049375212 title "Tocilizumab for severe COVID‐19 pneumonia: Case series of 5 Australian patients" @default.
• W3049375212 cites W2060970919 @default.
• W3049375212 cites W2147550589 @default.
• W3049375212 cites W2471732223 @default.
• W3049375212 cites W2597070792 @default.
• W3049375212 cites W2607034258 @default.
• W3049375212 cites W2890890047 @default.
• W3049375212 cites W2936019126 @default.
• W3049375212 cites W2938774134 @default.
• W3049375212 cites W2969893880 @default.
• W3049375212 cites W3008090866 @default.
• W3049375212 cites W3009314935 @default.
• W3049375212 cites W3009885589 @default.
• W3049375212 cites W3012421327 @default.
• W3049375212 cites W3016661132 @default.
• W3049375212 cites W3017340845 @default.
• W3049375212 cites W3025502129 @default.
• W3049375212 cites W3027105933 @default.
• W3049375212 doi "https://doi.org/10.1111/1756-185x.13913" @default.
• W3049375212 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7436606" @default.
• W3049375212 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32881350" @default.
• W3049375212 hasPublicationYear "2020" @default.
• W3049375212 type Work @default.
• W3049375212 sameAs 3049375212 @default.
• W3049375212 citedByCount "7" @default.
• W3049375212 countsByYear W30493752122020 @default.
• W3049375212 countsByYear W30493752122021 @default.
• W3049375212 countsByYear W30493752122022 @default.
• W3049375212 crossrefType "journal-article" @default.
• W3049375212 hasAuthorship W3049375212A5012416527 @default.
• W3049375212 hasAuthorship W3049375212A5012597525 @default.
• W3049375212 hasAuthorship W3049375212A5018125923 @default.
• W3049375212 hasAuthorship W3049375212A5026850267 @default.
• W3049375212 hasAuthorship W3049375212A5028175606 @default.
• W3049375212 hasAuthorship W3049375212A5030088258 @default.
• W3049375212 hasAuthorship W3049375212A5030697207 @default.
• W3049375212 hasAuthorship W3049375212A5036503908 @default.
• W3049375212 hasAuthorship W3049375212A5038396319 @default.
• W3049375212 hasAuthorship W3049375212A5044390712 @default.
• W3049375212 hasAuthorship W3049375212A5045920784 @default.
• W3049375212 hasAuthorship W3049375212A5048235044 @default.
• W3049375212 hasAuthorship W3049375212A5048487224 @default.
• W3049375212 hasAuthorship W3049375212A5049486575 @default.
• W3049375212 hasAuthorship W3049375212A5051274602 @default.
• W3049375212 hasAuthorship W3049375212A5063550038 @default.
• W3049375212 hasAuthorship W3049375212A5065071305 @default.
• W3049375212 hasAuthorship W3049375212A5065680312 @default.
• W3049375212 hasAuthorship W3049375212A5071551825 @default.
• W3049375212 hasAuthorship W3049375212A5072401570 @default.
• W3049375212 hasAuthorship W3049375212A5072544168 @default.
• W3049375212 hasAuthorship W3049375212A5074377658 @default.
• W3049375212 hasAuthorship W3049375212A5079436807 @default.
• W3049375212 hasAuthorship W3049375212A5088837358 @default.
• W3049375212 hasBestOaLocation W30493752121 @default.
• W3049375212 hasConcept C126322002 @default.
• W3049375212 hasConcept C141071460 @default.
• W3049375212 hasConcept C2776376669 @default.
• W3049375212 hasConcept C2777178219 @default.
• W3049375212 hasConcept C2777914695 @default.
• W3049375212 hasConcept C2779123688 @default.
• W3049375212 hasConcept C2779134260 @default.
• W3049375212 hasConcept C3008058167 @default.
• W3049375212 hasConcept C524204448 @default.
• W3049375212 hasConcept C71924100 @default.
• W3049375212 hasConceptScore W3049375212C126322002 @default.
• W3049375212 hasConceptScore W3049375212C141071460 @default.
• W3049375212 hasConceptScore W3049375212C2776376669 @default.
• W3049375212 hasConceptScore W3049375212C2777178219 @default.
• W3049375212 hasConceptScore W3049375212C2777914695 @default.
• W3049375212 hasConceptScore W3049375212C2779123688 @default.

• next